Keyphrases
Adaptive Radiotherapy
63%
Colorectal Cancer
41%
Adaptive Radiation Therapy
34%
Short-course Radiation Therapy
34%
Pancreatic Cancer
30%
Radiation Therapy
28%
MR-guided
28%
Stereotactic Body Radiation Therapy
26%
Clinical Outcomes
25%
Clinical Complete Response
23%
Nonoperative Management
22%
MR-guided Radiotherapy (MRgRT)
22%
Nonoperative
21%
Tumor
20%
Magnetic Resonance-guided
19%
Chemotherapy
19%
Overall Survival
19%
Resectable Pancreatic Cancer
18%
Magnetic Resonance Imaging
18%
Abdominal
18%
Total Neoadjuvant Therapy
18%
Radiation Oncology
17%
Linear Accelerator (LINAC)
16%
At-risk
16%
Gantry
15%
Computed Tomography-guided
15%
Confidence Interval
15%
On-table
14%
Lutetium-177 (177Lu)
14%
Carbamazepine
14%
Radiotherapy
14%
Halcyon
14%
Locally Advanced Rectal Cancer
14%
Rectal Adenocarcinoma
13%
MRI-guided
13%
Online Adaptive
12%
Cone-beam Computed Tomography
12%
Quality Assurance
12%
Ablative
12%
CT-guided
12%
Neuroendocrine Tumor
11%
Borderline Resectable
11%
Complete Response
11%
Nonclinical
11%
Circumferential Resection Margin
11%
Single Institution
10%
Adaptation Planning
10%
Radioprotection
10%
Irradiation
10%
PET-MRI
9%
Medicine and Dentistry
Radiation Therapy
100%
Adaptive Radiotherapy
54%
Rectum Cancer
51%
Magnetic Resonance Imaging
50%
Pancreas Cancer
43%
Neoplasm
41%
Adaptive Radiation
32%
Stereotactic Body Radiation Therapy
31%
Overall Survival
24%
Radiation Oncology
21%
Volume CT
20%
Diseases
20%
Neoadjuvant Therapy
19%
Computer Assisted Tomography
18%
Chemoradiotherapy
17%
Cancer Therapy
16%
Malignant Neoplasm
14%
Intensity Modulated Radiation Therapy
14%
Radioembolization
14%
Pancreas Adenocarcinoma
13%
Rectum Carcinoma
13%
Breathing
13%
Pelvis
13%
Prostate Cancer
12%
Surgical Margin
12%
Radiation Protection
12%
Lutetium 177
11%
Liver Cancer
11%
Cone Beam Computed Tomography
11%
Contouring
10%
Oncology
10%
Stereotactic Radiotherapy
10%
Progression Free Survival
10%
Image-Guided Radiation Therapy
9%
Protein P53
9%
Carbamazepine
9%
Autophagy
9%
Nitroxide
9%
Radiopharmaceutical
9%
Yttrium 90
9%
Distant Metastasis Free Survival
9%
Neuroendocrine Tumor
9%
Cancer
9%
Consolidation Chemotherapy
9%
Cholangiocarcinoma
9%
Recurrent Disease
8%
Health Care Cost
8%
Arm
8%
Ionization Chamber
7%
Gastrointestinal Toxicity
7%